Xin Qi-Qi, Yang Bin-Rui, Zhou He-Feng, Wang Yan, Yi Bo-Wen, Cong Wei-Hong, Lee Simon Ming-Yuen, Chen Ke-Ji
Clinical Medical College, Beijing University of Chinese Medicine, Beijing, 100029, China.
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, 999078, China.
Chin J Integr Med. 2018 Jul;24(7):494-501. doi: 10.1007/s11655-016-2262-2. Epub 2016 Jun 9.
OBJECTIVE: To investigate the pro-angiogenic effects of paeoniflorin (PF) in a vascular insufficiency model of zebrafish and in human umbilical vein endothelial cells (HUVECs). METHODS: In vivo, the pro-angiogenic effects of PF were tested in a vascular insufficiency model in the Tg(fli-1:EGFP)y1 transgenic zebrafish. The 24 h post fertilization (hpf) embryos were pretreated with vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor II (VRI) for 3 h to establish the vascular insufficiency model and then post-treated with PF for 24 h. The formation of intersegmental vessels (ISVs) was observed with a fluorescence microscope. The mRNA expression of fms-like tyrosine kinase-1 (flt-1), kinase insert domain receptor (kdr), kinase insert domain receptor like (kdrl) and von Willebrand factor (vWF) were analyzed by real-time polymerase chain reaction (PCR). In vitro, the pro-angiogenic effects of PF were observed in HUVECs in which cell proliferation, migration and tube formation were assessed. RESULTS: PF (6.25-100 μmol/L) could rescue VRI-induced blood vessel loss in zebrafish and PF (25-100 μmol/L), thereby restoring the mRNA expressions of flt-1, kdr, kdrl and vWF, which were down-regulated by VRI treatment. In addition, PF (0.001-0.03 μmol/L) could promote the proliferation of HUVECs while PF stimulated HUVECs migration at 1.0-10 μmol/L and tube formation at 0.3 μmol/L. CONCLUSION: PF could promote angiogenesis in a vascular insufficiency model of zebrafish in vivo and in HUVECs in vitro.
J Ethnopharmacol. 2017-11-7
J Ethnopharmacol. 2020-5-23
Mol Med Rep. 2011-12-15
Front Pharmacol. 2022-7-19
Chin J Integr Med. 2020-1
Evid Based Complement Alternat Med. 2018-11-21
Chin J Integr Med. 2021-1
Int J Clin Exp Pathol. 2015-1-1
Expert Opin Investig Drugs. 2013-6-22
Curr Opin Genet Dev. 2009-10-26